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Abstract
Background: Colon cancer has been classically described by clinicopathologic features that permit the prediction
of outcome only after surgical resection and staging.
Methods: We performed an unsupervised analysis of microarray data from 326 colon cancers to identify the first
principal component (PC1) of the most variable set of genes. PC1 deciphered two primary, intrinsic molecular
subtypes of colon cancer that predicted disease progression and recurrence.
Results: Here we report that the most dominant pattern of intrinsic gene expression in colon cancer (PC1) was
tightly correlated (Pearson R = 0.92, P < 10
-135) with the EMT signature– both in gene identity and directionality. In
a global micro-RNA screen, we further identified the most anti-correlated microRNA with PC1 as MiR200, known to
regulate EMT.
Conclusions: These data demonstrate that the biology underpinning the native, molecular classification of human
colon cancer–previously thought to be highly heterogeneous– was clarified through the lens of comprehensive
transcriptome analysis.
Background
Colon cancer has long been postulated to be a molecu-
larly heterogeneous disease. This heterogeneity has been
proposed as the reason why it has been difficult to iden-
tify unifying molecular hypotheses explaining the biol-
ogy and behavior of the disease. Molecular profiling of
colon cancer has been a relatively effective approach for
identifying prognosis of early and intermediate stage dis-
ease. We and others have identified biologically complex
signatures that affect multiple programs such as adhe-
sion, invasion, and angiogenesis and correlate well with
cancer progression and recurrence. These signatures
appear to support Weinberg’s hypothesis [1] of multiple
programs leading to cancer development and progres-
sion. These signatures have generally been developed
using supervised machine learning techniques that train
their models on pre-determined good vs. poor prognosis
patient populations [2-6]. Colon cancer, unlike breast
cancer where luminal and basal “intrinsic” subtypes have
been identified [7-13], or bladder cancer where intrinsic
signatures of recurrence have been established [14,15],
has yet to be classified by unsupervised,m o l e c u l a rp r o -
filing approaches. We believed it was important to
attempt to uncover unbiased, native biological traits that
might underpin colon cancer.
Methods
Colon Cancer Samples
326 human colon cancer samples derived from the Mof-
fitt Cancer Center were previously assessed using a sin-
gle Affymetrix U133Plus2.0 platform and single standard
operating procedure. Formalin fixed paraffin blocks
(FFPE) were obtained for 69 of these cases and used to
extract tumor RNA after macrodissection. Tumor RNA
was submitted for global microRNA analysis using an
Applied Biosystems platform covering ~700 unique
microRNA species. The gene expression data were then
compared directly to the microRNA data derived from
the same samples. All patient samples and clinical infor-
mation for the 326 colon samples were obtained
through a protocol approved by The University of South
Florida Institutional Review Board.
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The EMT signature was derived from a microarray data-
set with 93 lung cancer cell lines by performing a t-test
comparing cell lines exhibiting mesenchymal-like gene
expression pattern (high levels of VIM and low levels of
CDH1) vs. cell lines with epithelial-like gene expression
pattern (low levels of VIM and high levels of CDH1).
Genes with p-value < 0.01 by a t-test were selected, and
were split into those that were up-regulated in mesench-
ymal-like cell lines and those that were up-regulated in
epithelial like, and further restricted to approximately
2 0 0u n i q u eg e n es y m b o l si ne a c hu pa n dd o w nr e g u -
lated gene sets based on the absolute value of the fold
change.
Identification of PC1
Unsupervised analysis of the most variable genes
expressed in the colon cancer data set (n = 326) was
undertaken to discover new, “intrinsic” biology of colon
cancer. Principal component analysis on the entire gene
expression data set of 326 CRC samples, as implemen-
ted in the Princomp function in Matlab, (Mathworks
Inc.), was computed by selecting the 1st principal com-
ponent (PC1) corresponding to the highest eigenvalue of
the covariance matrix, describing the inherent variability
of the data.
Derivation of colon signatures
We identified a set of gene sets that were associated
with different endpoints related to tumor histology. Sig-
natures for each of the following scenarios was created:
right/left (RT/LT) colon was computed by comparing 60
samples collected in RT Colon vs. 18 samples collected
in LT Colon; Mucinous/Non-Mucinous colon carci-
noma was developed by comparing 35 mucinous colon
carcinomas vs. 165 non-mucinous; MSI/MSS was cre-
ated by comparing 6 MSI vs. 73 MSS samples; Carci-
noma vs. Adenoma was developed by comparing 22
pure adenocarcinoma samples vs. 5 pure adenomas;
Poor/Well differentiation was discovered by comparing
32 poorly differentiated samples vs. 19 well differen-
tiated, Colon/Rectum by comparing 50 samples col-
lected in colon vs. 19 samples collected in rectum;
Stage2/Stage1 was identified by comparing 59 stage 2
samples vs. 32 stage 1 samples, Stage 3/Stage 2 (71
Stage 3 samples vs. 59 Stage 2 samples) was similarly
identified. Each comparison was carried on non-metastatic
samples with known stage, histology, and collection site.
For each comparison, two gene sets (up and down regu-
lated) were identified by t-test with p-value < 0.01, split by
as i g no ff o l dc h a n g e ,s e l e c t i o no fu n i q u eg e n es y m b o l s
among 100 probes most differentially expressed by an
absolute value of fold change. Performance of these gene
sets was evaluated by back substitution and the scores for
gene sets were computed as the mean of probes mapped
by the gene symbol to the up-regulated subset minus the
mean of the probes that mapped by the gene symbol to
the down-regulated subset. They were found to have ROC
AUC>0.7 and 1-way ANOVA p-value < 1e-6 when applied
to distinguish the same samples that were used to identify
these gene sets.
Scoring of signatures in the data set
Signature score for a given gene set was obtained by
averaging the expression levels of the probes that
mapped by the gene symbol to that gene set. MYC and
RAS signatures were obtained from Nevins et al [16,17].
Standard microarray data processing
T h em i c r o a r r a yd a t aw a sp r o c e s s e db yr u n n i n gR M A
normalization method as implemented in Affymetrix
Power Tools using default settings, background correc-
tion and quantile normalization with subsequent appli-
cation of log10 to obtained probe intensities.
Results
We took a completely unsupervised approach to classi-
fying a set of 326 colon and rectal cancers from a
spectrum of clinical stages. We set out to identify the
most differentially expressed genes, and used the first
principal component (PC1) (~5000 differentially-
expressed genes) to describe two major subpopulations
(Figure 1a, b). The biology of the ~5000 genes under-
pinning the “intrinsic” PC1 signature was not forthcom-
ing from the standard functional analyses algorithms
that often identify multiple pathways linked to complex
signatures. In fact, analysis of PC1 by Ingenuity, Kegg,
and GeneGo approaches identified multiple potential
pathways that might be responsible for the observed
molecular subclassification (Additional File 1). This
approach did not precisely clarify the biology behind the
observed gene expression changes, but suggested that
adhesion and extracellular matrix were significantly
affected. To better describe the functionality of PC1, we
examined numerous (~300) cell line-derived and
tumor-derived signatures for their association with PC1.
This analysis identified the cell line derived epithelial-
mesenchymal transition gene expression signature as
the most significantly associated (P < 10
-135)w i t hP C 1
(Figure 1c). The signature was derived from an analysis
of 93 lung cancer cell lines that had been previously
globally molecularly profiled and sorted by two genes
associated with the EMT phenotype, CDH1 and VIM
(Figure 1d, Additional File 2). The cell lines were then
divided into two groups, one considered to be epithelial
(high CDH1, low VIM) and one considered mesenchy-
mal (low CDH1, high VIM) (Additional File 3). The two
groups were then used to identify ~300 genes that
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Page 3 of 10would further distinguish epithelial from mesenchymal
cell lines. This group of genes then became a cell line
derived “EMT signature”. More importantly, the up and
down arms of the EMT signature were directionally cor-
related with PC1 (P < 10
-16, Fisher Exact Test) (Addi-
tional File 4). The significant finding was that the
unsupervised PC1 signature, which represented an
“intrinsic” subtype classifier of colon cancer, appeared
to be driven by a core EMT program of up-and down-
regulated genes (Additional File 4). In fact, 92% of
probes mapped to EMT UP gene set (genes that were
up-regulated in mesenchymal vs. epithelial lung cell
lines) were positively correlated with PC1 and 82% of
probes from EMT DOWN gene set (genes that were
respectively down-regulated), corresponding to Fisher
exact test p-value of 2 × 10
-16 [18].
We further confirmed the expression of this same
embedded pattern of gene expression (PC1) in the inde-
pendent ExPO data set (n = 269) (Figure 1b), suggesting
that EMT is a pervasive program underpinning colon
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Figure 1 Intrinsic molecular stratification of human colorectal cancer. Unsupervised analysis and hierarchical clustering of global gene
expression data derived from colorectal cancer cases identified 2 major “intrinsic” subclasses (cyan and magenta) distinguished by the first
principal component (PC1) of the most variable genes. These two key native subtypes were clearly identified in both the (a) Moffitt Cancer
Center (MCC) data set (n = 326) and the (b) EXPO dataset (n = 269). PC1 was later found to be tightly correlated with an EMT signature derived
from cell lines, providing an explanation for the biology underpinning these two intrinsic classes in both datasets. PC1 clearly distinguishes two
subclasses which were subsequently identified as epithelial vs. mesenchymal. On both panels (a) and (b), mean-centered probe intensities are
shown, and probes are clustered using Pearson correlation based distance and Ward linkage. Also, rows represent samples, and columns
represent array probes. Panel (c) shows scatter plot of EMT signature score and PC1 (First Principal Component Score) on Moffitt Cancer Center
data set. Panel (D) shows the scatter plot between probe intensities for Vimentin (VIM) and E-cadherin probes in a panel of 93 Lung Cancer Cell
Lines. Cell Lines exhibiting epithelial-like phenotype are shown in green; those exhibiting mesenchymal-like phenotype are shown in red.
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Page 4 of 10cancer biology. To further clarify the EMT association
with the PC1 signature, genes previously linked to the
EMT program such as VIM, FGFR, FLT1, FN1, TWIST,
AXL, and TCF, were individually assessed and found to
be positively correlated with PC1/EMT (Figure 2). Simi-
l a r l y ,g e n e ss u c ha sC D H 1 ,C L D N 9 ,E G F R ,a n dM E T
were negatively correlated with PC1/EMT. Also shown
are multi-gene signatures (black labels) such as EMT,
TGF-beta, RAS, proliferation, and MYC; TGF-beta is a
known driver of EMT and thus correlates with both PC1
and EMT. Alternatively, RAS activation/dependency/
addiction has been shown to anti-correlate with EMT
[19]. K-RAS dependent cells exhibit an epithelial mor-
phology, expressing significant cortical CDH1 but little
VIM. Conversely, RAS-independent cells express little
CDH1 but significant VIM. Our results are consistent
with these findings. Of interest, proliferation, and an
effecter of such (MYC), both anti-correlate with EMT.
To determine if the EMT signature might be regulated
by specific microRNAs [20], we re-profiled ~70 Stage I-
IV colon cancers with a ~415 global MiR platform that
had been previously assessed by microarray analysis.
Out of these ~70 samples, 49 were subsequently used
for the analysis after data processing and QC. Of all the
MiRs tested, the MiR 200 family was the most highly
anti-correlated with PC1/EMT signatures (Figure 3,
Additional File 5, Additional File 6). Whereas the gene
expression analysis to derive PC1 was performed from
frozen tissues, the MiR analyses were performed using
matched formalin-fixed, paraffin-embedded tissues
(FFPE), strengthening the observed finding across
platforms.
Having identified PC1 as an intrinsic gene expression
signature closely linked to the EMT program, we
wanted to determine if the mesenchymal phenotype
(high PC1/EMT score) would predict recurrence of dis-
ease. To our surprise, PC1, despite being developed with
an unsupervised approach, was capable of differentiating
good from poor prognosis, and was well-correlated with
recurrence and progression of disease, even for
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Figure 2 Hierarchical cluster analysis of the top 100 genes assessed from a text mining approach were strongly associated with the
EMT program as shown on 326 MCC colon tumors sorted by PC1. The 100 gene set contains individual genes (CDH1, CLDN9, FGFR1, FN1,
TWIST 1 & 2, AXL, VIM) as well as signatures of genes (PC1, EMT, TGFbeta, Proliferation, MYC, and RAS) that are up-regulated in mesenchymal
tumors (shown in magenta), and that are up-regulated in epithelial tumors (shown in cyan). Names for the relevant gene signatures are shown
in black. Samples (rows) are sorted by PC1. Genes (columns) are clustered using Pearson correlation and Ward linkage. Heatmap shows mean-
centered probe intensities.
Loboda et al. BMC Medical Genomics 2011, 4:9
http://www.biomedcentral.com/1755-8794/4/9
Page 5 of 10intermediate stages II and Stage III (Figure 4a, Addi-
tional File 7, 8, 9, 10). It was also linked to cancer pro-
gression and to poor differentiation status. We further
identified these relationships in the Lin et al [21], NKI,
and EXPO data sets (Additional File 11). Moreover, PC1
was also predictive of disease-free survival in the Moffitt
Cancer Center colon cancer data set (Figure 4b). More
importantly, however, PC1 was also predictive of poor
outcome in two additional completely independent data
sets. In a data set from the NKI, PC1 predicted metasta-
sis free survival (Figure 4c) and in a Lin et al data set
[21], PC1 predicted recurrence (Figure 4d). When the
PC1 signature is applied to cancers with different recur-
rence rates, there was also a clear difference between
colon, lung, and pancreas cancers (colon < lung < pan-
creas) (Additional Files 12, 13, 14, 15and 16).
We also tested known signatures, or developed a num-
ber of other signatures within the colon cancer dataset,
that did not correlate well with PC1. These included a
signature predicting MSI status [22], a signature
s e p a r a t i n gr i g h tf r o ml e f tc o l o nt u m o r s ,as i g n a t u r e
separating mucinous from non-mucinous tumors, and a
proliferation signature [23] (Figure 4a). The PC1 signa-
ture, while discriminating for epithelial vs mesenchymal
tumors, may also be used to classify cell lines. This clas-
sification undoubtedly will be useful in further analysis
of EMT in cancer using these cell lines as models.
Understanding which cell lines best represent the
epithelial vs the mesenchymal phenotype will help deter-
mine the best models for subsequent drug intervention
and target validation studies and will allow cell lines to
be mapped to human tumors. For this purpose, we have
classified numerous colon cell lines using the tumor-
derived PC1 signature (Additional File 16).
Discussion
Colon cancer has heretofore been considered a very het-
erogeneous disease [24,25]. It has been difficult to iden-
tify a unifying biological theme that could be leveraged
for therapeutic intervention. Previously identified
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Figure 3 Correlation of microRNA analysis (~700) with PC1/EMT across 49 colorectal cancers identified the MiR200 family as strongly,
negatively correlated with PC1/EMT (upper plots). The Mir 200 family has been linked to inhibition of EMT (promotion of the epithelial
phenotype) through inhibition of Zeb 1 & 2, known transcriptional repressors of CDH1. Waterfall plots show MiR 200 over-expression is correlated
with more tumors classified as epithelial than mesenchymal and Mir 200 under-expression is correlated with fewer epithelial than mesenchymal
tumors (lower plots).
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Page 6 of 10prognostic signatures have required supervised learning
to elucidate predictive gene sets. For the first time, our
data suggest that the PC1 signature, discovered through
unsupervised approaches, appears to be a native, intrin-
sic subtype classifier of colon cancer that predicts recur-
rence, advancing stage, and poor prognosis based on the
biology of EMT. Finding the PC1 score was predictive
of recurrence for both stages II and III of colon cancer,
and its strong relationship to EMT biology, leads to the
possibility that this signature might be useful in these
stages for discerning responsiveness to adjuvant che-
motherapy. Our data suggest the otherwise molecularly
and pathologically heterogeneous disease may be
resolved into two principal molecular subtypes of colon
cancer: epithelial or mesenchymal.
The identification of the intrinsic EMT program was
further supported by additional molecular studies relat-
ing global microRNA profiling data to global gene
expression datasets. From this analysis, the MiR 200
family and related MiRs were identified as highly nega-
tively correlated with PC1. This finding was significant
because the MiR 200 family has been closely linked to
the EMT program. It has been previously demonstrated
that MiR 200 over-expression may result in inhibition of
ZEB1/2, which in turn leads to inhibition of transcrip-
tional repressors of CDH1, thereby permitting the
expression of CDH1 and expression of the epithelial
phenotype [26,27]. Thus, a negative correlation of
MiR200 and the EMT signature promoting a mesenchy-
mal phenotype is consistent. The relationship between
b. a.
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Figure 4 Covariance matrix showing correlation of PC1 with disease recurrence. (a) PC1, despite being developed with unsupervised
approaches, appeared to correlate well with EMT, disease recurrence, disease progression, and differentiation status, but not with gene
signatures linked to adenoma vs. carcinoma, MSI status, or mucinous vs. nonmucinous cancers. Moreover, PC1 appeared to be anti-correlated
with RAS, MYC, Proliferation, and colon laterality. PC1 distinguishes good and poor prognosis patients in the MCC data set (b) as well as in two
independent test sets: (c) Netherlands Cancer Institute (NKI, #13) (L.V.V.) and (d) Lin et al data sets [21].
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Page 7 of 10MiR 200 and PC1 was strong enough to be detected on
a relatively small number of tumors, even when non-
mirror image FFPE tissues were used instead of the ori-
ginal frozen specimen, suggesting the EMT program is
pervasive throughout the primary tumor. In addition,
MiR 141, a MiR 200 family member, was also identified
as negatively correlated with EMT, confirming previous
observations. Finally, numerous additional MiRs have
been identified that have not yet been previously
reported to be linked to EMT.
Analysis of PC1 relative to biological programs beyond
EMT was also informative. Of interest was that MSI
tumors which are generally prone to better prognosis
and right sided predisposition, were shown to have rela-
tively low PC1 scores. Consistent with these data, recent
studies have supported the hypothesis that MSI tumors
are anti-correlated with EMT [28]. Similarly, mucinous
tumors have been linked to local more than distant
recurrence, thus the finding that these tumors were
more epithelial than mesenchymal is biologically consis-
tent. Most interesting was that the proliferation signa-
ture, which has been previously used to identify poor
prognosis breast and lung cancers, was linked to good
prognosis colon tumors, suggesting proliferation may
not play a critical role in colon cancer progression, yet
we know it is important for colon epithelial biology in
crypt bases. Consistent with this is the recent observa-
tion that colon metastases have a lower proliferative
index than primary non-metastatic tumors [29]. One
explanation for this observation may be that metastatic
lesions may have undergone a mesenchymal to epithelial
transition (MET) [30]. Thus, PC1, a harbinger of the
transition to the mesenchymal state, is predictive of
poor vs good outcome in a number of observed clinical
scenarios. These PC1 anti-correlated signatures shed
further light on the biology of colon cancer.
Our data also support the concept that the mesenchy-
mal subtype, linked to TGF-B activation, is likely
responsible for advancing stage, poor differentiation sta-
tus, and distant recurrence of disease, but not to RAS,
MYC, MSI, or proliferation. RAS activation, linked to
the epithelial phenotype driven by genes such as EGFR,
appears to be anti-correlated with the PC1/EMT or
mesenchymal signature.
Analysis of other cancers such as pancreas and lung
demonstrate a spectrum of EMT across diseases (colon
< lung < pancreas) that may explain the differential sur-
vivability of these cancers (colon > lung > pancreas),
variable recurrence rates, and responses to therapy [31].
And, as we have shown, these observations can now be
leveraged to classify cell lines for therapeutic interven-
tion modeling. We anticipate the PC1 score may be use-
ful in classifying tumors with a mesenchymal vs.
epithelial phenotype that might be sensitive to new
classes of drugs such as Src, Notch, and FGFR inhibitors
vs EGFR inhibitors, respectively.
Conclusions
Collectively, our data suggest that the “intrinsic” PC1
signature, underpinned by robust EMT biology, is highly
prognostic for colon cancer recurrence, may be useful
to subclassify more than one type of cancer, and may
provide a means of identifying sensitive subpopulations
for the next generation of novel therapeutics.
Additional material
Additional file 1: Ingenuity/GO Analysis produced multiple
functional categories for PC1 without bringing clarity to the
underlying biology. The table lists top functional gene groups in terms
of significance for enrichment of genes from PC1 signature. Both,
significance of enrichment p-value,(based on hyper geometric
distribution) and Bonferroni-type correction e-value (to account for
multiple testing). Gene sets from Ingenuity, KEGG, and GeneGO were
included in the analysis.
Additional file 2: EMT signature was derived by comparing gene
expression of cell lines sorted into epithelial or mesenchymal like
groups based on CDH1 and VIM expression (see Additional Figure
1). The top 200 up and down probes found most significant by ANOVA
(P < 0.001) were selected to represent the EMT signature. The EMT
signature contains known EMT drivers such as ZEB1 and ZEB2, TCF4, AXL.
It also contains markers such as CDH1, CDH3 for epithelial phenotype
and VIM, CDH2 and CDH4 for the mesenchymal phenotype.
Additional file 3: miRNA correlation to EMT and RAS signature
scores on mean-centered data. Pearson correlation coefficient and the
associated p-value are provided.
Additional file 4: Centered abundances for 49 tumors × 416 MiR
detectors.
Additional file 5: Out of ~300 signatures tested, EMT was the most
significantly associated with PC1 in colon (P < 10
-135). More
importantly, the up and down arms of the EMT signature were
directionally correlated with PC1 (P < 10
-16, Fisher Exact Test). See
Additional File 2 for list of genes.
Additional file 6: Derivation of the EMT signature used to clarify
the biology characterizing PC1. The EMT signature was derived from a
global gene expression analysis of 93 lung cancer cell lines first
segregated by differential CDH1 and VIM expression. Right panel shows
the relationship between EMT signature score and CDH1 probe
intensities, the left panel shows the EMT signature score vs. VIM probe
intensity. EMT signature is observed to be positively correlated to VIM
and anticorrelated to CDH1.
Additional file 7: Waterfall plot of recurrence prediction of PC1 for
the MCC colon dataset shows more recurrences with high signature
scores than with low signature scores; similarly there fewer
recurrences with low signature scores than with high signature
scores.
Additional file 8: Hierarchical cluster analysis showing expression of
key genes (red and blue) and gene signatures (black) in the EMT
signature for colorectal tumors. Genes positively correlated with the
EMT signature are shown in red and genes negatively correlated with
the EMT signature are shown in blue.
Additional file 9: Hierarchical cluster analysis showing expression of
key genes (red and blue) and gene signatures (black) in the EMT
signature for lung tumors. Genes positively correlated with the EMT
signature are shown in red and genes negatively correlated with the
EMT signature are shown in blue.
Additional file 10: Hierarchical cluster analysis showing expression
of key genes (red and blue) and gene signatures (black) in the EMT
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Page 8 of 10signature for pancreatic tumors. Genes positively correlated with the
EMT signature are shown in red and genes negatively correlated with
the EMT signature are shown in blue.
Additional file 11: Waterfall and boxplot analysis’s shows a
differential EMT score for colon < lung < pancreas following
normalization across all samples.
Additional file 12: Top 5000 most variable genes (columns) on
Colon cell lines (rows) sorted by PC1. PC1 is observed to be positively
correlated to EMT signature score and anti-correlated to RAS signature
score. Genes are clustered using Pearson correlation distance metric and
Ward linkage. Heatmap shows mean-centered probe intensities.
Additional file 13: PC1 predicts recurrence in stages 2 and 3 of
colon cancer. Data is shown for MCC dataset.
Additional file 14: Covariance matrices showing the relationship of
PC1 to the same endpoints as shown in Figure 4a using (a)
independent colon dataset [21] (b) EXPO dataset, (c) NKI dataset.
Additional file 15: EMT signature proposed in this paper is
predictive of recurrence in stage 2 and stage 3 MCC tumors.
Additional file 16: EMT signature proposed in this paper is
predictive of recurrence when applied to all tumor samples in MCC
data set.
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EMT: Epithelial Mesenchymal Transition; PC1: First Principal Component;
MET: Mesenchymal Epithelial Transition.
Acknowledgements
Supported by the National Institutes of Health, National Cancer Institute
Grant CA112215 (T. J.Y.) and The Florida Department of Health Bankhead-
Coley Cancer Research Program Grant: 08BR-02. We thank Magaly Mendez
and Mike Gruidl for manuscript preparation.
Funding
Funding for this work was provided by Merck & Co as well as NIH Grant:
CA112215.
Authors
All authors have read and approved the final manuscript.
Author details
1Merck, Sharp and Dohme, P.O. Box 4, 770 Sumneytown Pike, Building 53,
West Point, PA 19486, USA.
2Merck, Sharp and Dohme, P.O. Box 4, 770
Sumneytown Pike, WP53B-120, West Point, PA 19486, USA.
3Merck Research
Laboratories, UG-4C74, 351 N. Sumneytown Pike, North Wales, PA 19454-
2505, USA.
4Merck, Sharp and Dohme, 33 Avenue Louis Pasteur, Boston, MA
02115, USA.
5Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612,
USA.
6LIFE Biosystems GmbH, Poststrasse 34, D-69115 Heidelberg, Germany.
7Diagnostic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121,
1066 CX, Amsterdam, The Netherlands.
8Leiden University Medical Center,
PO Box 9600 2300 RC Leiden, The Netherlands.
Authors’ contributions
AL, MN, JW, CB, DH performed data analysis, interpreted the results, and
created figures for the manuscript. PS and PH provided scientific direction,
critical review and data interpretation. LVV and RT provided clinical samples
for the test set. DA provided scientific input into the design and analysis of
the experiments. AL and TY were the lead authors of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 July 2010 Accepted: 20 January 2011
Published: 20 January 2011
References
1. Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell 2000, 100(1):57-70.
2. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M,
Cantor A, Coppola D, Yeatman TJ: Osteopontin identified as lead marker
of colon cancer progression, using pooled sample expression profiling. J
Natl Cancer Inst 2002, 94(7):513-521.
3. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D,
Kruhoffer M, Aaltonen L, Orntoft TF, et al: Molecular staging for survival
prediction of colorectal cancer patients. J Clin Oncol 2005,
23(15):3526-3535.
4. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D,
Aaltonen LA, Arango D, Kruhoffer M, et al: Metastasis-Associated Gene
Expression Changes Predict Poor Outcomes in Patients with Dukes
Stage B and C Colorectal Cancer. Clin Cancer Res 2009, 15(24):7642-7651.
5. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P,
Johnson JC, Schmidt C, Bailey CE, et al: Experimentally derived metastasis
gene expression profile predicts recurrence and death in patients with
colon cancer. Gastroenterology 2010, 138(3):958-968.
6. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL,
Atkins D: Gene expression profiles and molecular markers to predict
recurrence of Dukes’ B colon cancer. J Clin Oncol 2004, 22(9):1564-1571.
7. Malvezzi M, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Decarli A:
Cancer mortality in Italy, 2003. Tumori 2009, 95(6):655-664.
8. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J,
Debono S, Houvenaeghel G, Maraninchi D, Viens P, et al: Gene expression
profiling shows medullary breast cancer is a subgroup of basal breast
cancers. Cancer Res 2006, 66(9):4636-4644.
9. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C,
Nguyen C, Xerri L, Houlgatte R, Jacquemier J, et al: Gene expression
profiling identifies molecular subtypes of inflammatory breast cancer.
Cancer Res 2005, 65(6):2170-2178.
10. Bertucci F, Orsetti B, Negre V, Finetti P, Rouge C, Ahomadegbe JC, Bibeau F,
Mathieu MC, Treilleux I, Jacquemier J, et al: Lobular and ductal carcinomas
of the breast have distinct genomic and expression profiles. Oncogene
2008, 27(40):5359-5372.
11. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G,
Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with
breast cancer clinical outcome depend on the molecular subtypes. Clin
Cancer Res 2008, 14(16):5158-5165.
12. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, d’Assignies MS, et al: Strong time dependence of
the 76-gene prognostic signature for node-negative breast cancer
patients in the TRANSBIG multicenter independent validation series. Clin
Cancer Res 2007, 13(11):3207-3214.
13. Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK, Liotcheva VB,
Jones EL, Vujaskovic Z, Marks J, et al: Gene expression profiles of multiple
breast cancer phenotypes and response to neoadjuvant chemotherapy.
Clin Cancer Res 2006, 12(3 Pt 1):819-826.
14. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S,
Knowles M, Malmstrom PU, de la Torre M, et al: Gene expression
signatures predict outcome in non-muscle-invasive bladder carcinoma: a
multicenter validation study. Clin Cancer Res 2007, 13(12):3545-3551.
15. Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR,
Parker AS, Goodison S: Bladder cancer-associated gene expression
signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol
Biomarkers Prev 2009, 18(2):444-453.
16. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D,
Lancaster JM, Berchuck A, et al: Oncogenic pathway signatures in human
cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357.
17. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D’Amico M,
Pestell RG, West M, Nevins JR: Gene expression phenotypic models that
predict the activity of oncogenic pathways. Nat Genet 2003, 34(2):226-230.
18. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W,
Roberts B, Zhang T, Chenard M, Haines B, et al: A gene expression
signature of RAS pathway dependence predicts response to PI3K and
RAS pathway inhibitors and expands the population of RAS pathway
activated tumors. BMC Med Genomics 3:26.
19. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N,
Settleman J: A gene expression signature associated with “K-Ras
addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell
2009, 15(6):489-500.
20. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D,
Coukos G, Zhang L, Huang Q: KLF17 is a negative regulator of epithelial-
mesenchymal transition and metastasis in breast cancer. Nat Cell Biol
2009, 11(11):1297-1304.
Loboda et al. BMC Medical Genomics 2011, 4:9
http://www.biomedcentral.com/1755-8794/4/9
Page 9 of 1021. Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V,
Thompson-Fawcett M, Kasabov N, Toro T, et al: Multiple gene expression
classifiers from different array platforms predict poor prognosis of
colorectal cancer. Clin Cancer Res 2007, 13(2 Pt 1):498-507.
22. Kruhoffer M, Jensen JL, Laiho P, Dyrskjot L, Salovaara R, Arango D,
Birkenkamp-Demtroder K, Sorensen FB, Christensen LL, Buhl L, et al: Gene
expression signatures for colorectal cancer microsatellite status and
HNPCC. Br J Cancer 2005, 92(12):2240-2248.
23. Enriquez JM, Diez M, Tobaruela E, Lozano O, Dominguez P, Gonzalez A,
Muguerza JM, Ratia T: Clinical, histopathological, cytogenetic and
prognostic differences between mucinous and nonmucinous colorectal
adenocarcinomas. Rev Esp Enferm Dig 1998, 90(8):563-572.
24. Mojica W, Hawthorn L: Normal colon epithelium: a dataset for the
analysis of gene expression and alternative splicing events in colon
disease. BMC Genomics 2010, 11:5.
25. Reid JF, Gariboldi M, Sokolova V, Capobianco P, Lampis A, Perrone F,
Signoroni S, Costa A, Leo E, Pilotti S, et al: Integrative approach for
prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes
Cancer 2009, 48(11):953-962.
26. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA,
Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate
epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat
Cell Biol 2008, 10(5):593-601.
27. Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the
epithelial phenotype of cancer cells by targeting the E-cadherin
repressors ZEB1 and ZEB2. Genes Dev 2008, 22(7):894-907.
28. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY,
Iafrate AJ, Zukerberg LR, Chung DC: Epithelial to mesenchymal transition
is impaired in colon cancer cells with microsatellite instability.
Gastroenterology 2010, 138(4):1406-1417.
29. Ganepola GA, Mazziotta RM, Weeresinghe D, Corner GA, Parish CJ,
Chang DH, Tebbutt NC, Murone C, Ahmed N, Augenlicht LH, et al: Gene
expression profiling of primary and metastatic colon cancers identifies a
reduced proliferative rate in metastatic tumors. Clinical & experimental
metastasis 2010, 27(1):1-9.
30. Vincan E, Barker N: The upstream components of the Wnt signalling
pathway in the dynamic EMT and MET associated with colorectal cancer
progression. Clinical & experimental metastasis 2008, 25(6):657-663.
31. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN,
Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al: Annual report
to the nation on the status of cancer, 1975-2006 featuring colorectal
cancer trends and impact of interventions (risk factors, screening, and
treatment) to reduce future rates. Cancer 2010, 116(3):544-573.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/4/9/prepub
doi:10.1186/1755-8794-4-9
Cite this article as: Loboda et al.: EMT is the dominant program in
human colon cancer. BMC Medical Genomics 2011 4:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Loboda et al. BMC Medical Genomics 2011, 4:9
http://www.biomedcentral.com/1755-8794/4/9
Page 10 of 10